We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Rapid and Sensitive Lateral Flow Test for Diagnosis of Schistosomiasis

By LabMedica International staff writers
Posted on 01 Dec 2021
A novel lateral flow immunoassay enables the rapid and sensitive diagnosis of the urogenital form of schistosomiasis in both laboratory and field settings.

Schistosoma haematobium is the most common cause of urogenital schistosomiasis in humans, responsible for infection in approximately half of the estimated 200 million people with the disease throughout the world's tropical and subtropical regions. More...
Although there is no gold-standard recommended technique for detection of schistosomiasis, a widely used method for diagnosing infection involves microscopy-based detection of parasite eggs in urine, which can have poor sensitivity in areas of low transmission, limiting its diagnostic value in regions where the disease is present but uncommon.

Investigators at James Cook University (Cairns, Australia) screened the family of proteins secreted by the S. haematobium parasite to identify antibody biomarkers of schistosome infection, validate their diagnostic performance in samples from endemic populations, and evaluate their utility for use in point-of-care immunochromatographic tests (POC-ICTs) to diagnose urogenital schistosomiasis.

The initial screening study with serum and urine antibodies from endemic populations in Gabon, Tanzania, and Zimbabwe was carried out by collaborators at the University of Southern California (Los Angeles, USA), who fit nearly a thousand different S. haematobium antigens onto a microarray chip. Antigens that were found to be IgG-reactive were then evaluated by ELISA using both the same samples as well as additional samples from individuals residing in a low-endemicity settings (ie, Pemba and Unguja islands, Zanzibar, and Tanzania).

Results revealed that 208 antigens were the targets of significantly elevated IgG responses in serum, and 45 antigens were the targets of significantly elevated IgG responses in urine. Of the five proteins that were validated by ELISA, Sh-TSP-2 and MS3_01370 displayed the highest overall diagnostic performance in each biofluid and exceeded that of S. haematobium-soluble egg antigen in urine. When incorporated into separate POC-ICTs, Sh-TSP-2 showed absolute specificity and a sensitivity of 75% and MS3_01370 showed absolute specificity and a sensitivity of 89%. Thus, the Sh-TSP-2 and MS3_01370 antigens could be used as sensitive, specific, and field-deployable diagnostic biomarkers to support schistosomiasis control and elimination.

“This is a disease of poverty,” said first author Dr. Mark Pearson, research fellow at James Cook University. “Although there are effective drugs available to treat it, it becomes a serious health issue where contaminated drinking water and waterways lead to frequent reinfections. To interrupt the spread of the disease, a test needs to be sensitive enough to identify people with low-level infections, who can still pass the parasite on to others when they might not know they are infected themselves.”

The POC assay for schistosomiasis was described in the August 31, 2021, online edition of the journal The Lancet Microbe.

Related Links:
James Cook University
University of Southern California



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.